Business Context and Reporting Period
Company: Lucid Diagnostics Inc. (LUCD)
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2026
Event: Closing of a previously announced underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics related to the transaction include:
- Shares Sold: 18,000,000 shares of common stock.
- Offering Price: $1.00 per share.
- Gross Proceeds: $18.0 million (calculated).
- Net Proceeds: Approximately $16.8 million (after underwriting discounts and estimated expenses).
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in the company's cash liquidity and the expansion of its share count due to the issuance of 18 million new shares. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes.
Underwriters: Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners.
Regulatory Context: The offering was conducted pursuant to an existing shelf registration statement (Form S-3, No. 333-291981) declared effective on March 26, 2026.
Risks/Contingencies: The filing text does not explicitly detail specific risks or contingencies beyond standard offering disclosures.
Investor Verification Checklist
- Verify the exact dilution impact of the 18,000,000 new shares on existing shareholders.
- Confirm the final net proceeds after all closing expenses are finalized.
- Review the attached press release (Exhibit 99.1) for any additional strategic context regarding the use of funds.
- Check subsequent filings for updates on the company's cash position and burn rate.